PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9748494-13	1998	The bimolecular rate constants for hydrolysis of aspirin by wild-type, D70G and D70K enzymes were found to be close to 1x106 M-1 min-1.	Aspirin	49-56	CD59 molecule (CD59 blood group)	Homo sapiens	129-134	
10564709-6	1999	Kinetic studies in placentae taken from aspirin-treated pregnancies showed that L-arginine is transported with a significantly higher affinity (Km = 42.5 +/- 5.7 microM), but with a lower capacity (Vmax = 0.064 +/- 0.003 micromol min-1) than in the non-treated group.	Aspirin	40-47	CD59 molecule (CD59 blood group)	Homo sapiens	230-235	
18967757-6	1999	In optimized conditions (flow rate of 2.1 ml min(-1) and volume of injection of 150 mul), the tubular electrode showed a linear response to ASA in the concentration range between 4.0x10(-3) and 4.0x10(-2) mol l(-1).	Aspirin	140-143	CD59 molecule (CD59 blood group)	Homo sapiens	45-51	
29314596-12	2018	Of the patients, 95% were found to be sensitive to ASA, with values under the threshold of normality (400 AU min-1 ).	Aspirin	51-54	CD59 molecule (CD59 blood group)	Homo sapiens	109-114	
8222512-8	1993	for aspirin-sensitive asthmatic patients [15.9 (SD 6.9) nmol min-1 mg-1 of protein] was not significantly different from that for the normal subjects.	Aspirin	4-11	CD59 molecule (CD59 blood group)	Homo sapiens	61-71	
1451711-7	1992	Creatinine clearance was 13.2 (95% CI 6.0 to 20.4) ml.min-1 lower in users than non-users of non-aspirin non-steroidal anti-inflammatory drugs.	Aspirin	97-104	CD59 molecule (CD59 blood group)	Homo sapiens	54-59	
2590612-4	1989	This dose of aspirin caused more than a 5 fold increase in gastric bleeding, from control values of 0.5 microliters 10 min-1 (95% confidence limits 0.3-0.8 microliters 10 min-1) to 2.8 microliters 10 min-1 (1.9-4.1 microliters 10 min-1, P less than 0.01) after 5 days of aspirin.	Aspirin	13-20	CD59 molecule (CD59 blood group)	Homo sapiens	119-124	
2590612-4	1989	This dose of aspirin caused more than a 5 fold increase in gastric bleeding, from control values of 0.5 microliters 10 min-1 (95% confidence limits 0.3-0.8 microliters 10 min-1) to 2.8 microliters 10 min-1 (1.9-4.1 microliters 10 min-1, P less than 0.01) after 5 days of aspirin.	Aspirin	13-20	CD59 molecule (CD59 blood group)	Homo sapiens	171-176	
2590612-4	1989	This dose of aspirin caused more than a 5 fold increase in gastric bleeding, from control values of 0.5 microliters 10 min-1 (95% confidence limits 0.3-0.8 microliters 10 min-1) to 2.8 microliters 10 min-1 (1.9-4.1 microliters 10 min-1, P less than 0.01) after 5 days of aspirin.	Aspirin	13-20	CD59 molecule (CD59 blood group)	Homo sapiens	171-176	
2590612-4	1989	This dose of aspirin caused more than a 5 fold increase in gastric bleeding, from control values of 0.5 microliters 10 min-1 (95% confidence limits 0.3-0.8 microliters 10 min-1) to 2.8 microliters 10 min-1 (1.9-4.1 microliters 10 min-1, P less than 0.01) after 5 days of aspirin.	Aspirin	13-20	CD59 molecule (CD59 blood group)	Homo sapiens	171-176	
29520080-13	2018	Among patients with minor stroke or TIA taking clopidogrel-aspirin treatment, CYP2C19 LOF carrier state was associated with higher risk of new stroke in those with eGFR < 75 ml/min/1.73 m2.	Aspirin	59-66	CD59 molecule (CD59 blood group)	Homo sapiens	180-185	
2590612-5	1989	Adaptation did not occur and the gastric bleeding rates remained elevated at 3.4 microliters 10 min-1 (1.9-6.1 microliters 10 min-1) after 12 days of aspirin consumption (P less than 0.01).	Aspirin	150-157	CD59 molecule (CD59 blood group)	Homo sapiens	126-131	
2590612-7	1989	Coadministration of ranitidine significantly raised intragastric pH and reduced aspirin induced bleeding to 1.5 microliters 10 min-1 (1.0-2.3 microliters 10 min-1) after 5 days and 1.6 (1.0-2.5 microliters 10 min-1) after 12 days (P less than 0.05).	Aspirin	80-87	CD59 molecule (CD59 blood group)	Homo sapiens	127-132	
2789070-7	1989	Aspirin increased bleeding from a rate on placebo of 1.2 microliters 10 min-1 geometric mean (95% confidence limits) (0.7-1.8) microliters 10 min-1 to 20.0 (11.6-34.2) microliters 10 min-1, (P less than 0.01).	Aspirin	0-7	CD59 molecule (CD59 blood group)	Homo sapiens	72-77	
2789070-7	1989	Aspirin increased bleeding from a rate on placebo of 1.2 microliters 10 min-1 geometric mean (95% confidence limits) (0.7-1.8) microliters 10 min-1 to 20.0 (11.6-34.2) microliters 10 min-1, (P less than 0.01).	Aspirin	0-7	CD59 molecule (CD59 blood group)	Homo sapiens	142-147	
2789070-7	1989	Aspirin increased bleeding from a rate on placebo of 1.2 microliters 10 min-1 geometric mean (95% confidence limits) (0.7-1.8) microliters 10 min-1 to 20.0 (11.6-34.2) microliters 10 min-1, (P less than 0.01).	Aspirin	0-7	CD59 molecule (CD59 blood group)	Homo sapiens	142-147	
2789070-8	1989	The rate of bleeding after aspirin preceded by ethamsylate [14.1 (8.5-23.4) microliters 10 min-1] was not significantly different from that after aspirin alone.	Aspirin	27-34	CD59 molecule (CD59 blood group)	Homo sapiens	91-96	
19155536-7	2009	For regular users of aspirin, the progression rate was significantly slower than that for non-regular users (regular users progressed 0.80 mL/min/1.73 m(2) per year slower than non-regular users; 95% CI 0.1, 1.5).	Aspirin	21-28	CD59 molecule (CD59 blood group)	Homo sapiens	142-147	
24743611-8	2015	However, preoperative aspirin use was associated with a significant decrease in postoperative AKI and 30-day mortality in patients with CKD undergoing cardiac surgery, in particular, the survival benefit associated with aspirin was greater in patients with CKD (vs normal kidney function): 30-day mortality was reduced by 23.3%, 58.2%, or 70.0% for patients with baseline eGFR more than or equal to 90, 30 to 59, or 15 to 30 mL/min/1.73 m2, respectively (P trend < 0.001).	Aspirin	22-29	CD59 molecule (CD59 blood group)	Homo sapiens	428-433	
24743611-8	2015	However, preoperative aspirin use was associated with a significant decrease in postoperative AKI and 30-day mortality in patients with CKD undergoing cardiac surgery, in particular, the survival benefit associated with aspirin was greater in patients with CKD (vs normal kidney function): 30-day mortality was reduced by 23.3%, 58.2%, or 70.0% for patients with baseline eGFR more than or equal to 90, 30 to 59, or 15 to 30 mL/min/1.73 m2, respectively (P trend < 0.001).	Aspirin	220-227	CD59 molecule (CD59 blood group)	Homo sapiens	428-433	
15600265-11	2004	In severe kidney disease (GFR 15-29 mL/min/1.73 m2), the hazards risk for death was 0.21 (0.08, 0.53) for aspirin alone, 0.17 (0.06, 0.51) for aspirin with beta-blockers, and 0.35 (0.09, 1.42) for aspirin with beta-blockers and ace-inhibitors.	Aspirin	106-113	CD59 molecule (CD59 blood group)	Homo sapiens	39-44